the aid library

LIST OPTIONS

Filter

9702

Policy Snapshot: Cholesterol Control and Management in Brazil

World Heart Federation (2015) CC

Worldwide, there are about 17 million deaths due to cardiovascular disease (CVD) each year and at least two or three times as many non-fatal events. Raised cholesterol greatly increases the risks of stroke and heart disease, causing a large health burden across the world. The World Health Organizat... more

Download (294)

View PDF (486)

Children’s Ebola Recovery Assessment: Sierra Leone

Isabelle Risso-Gill and Leah Finnegan UNICEF; Save the Children; Plan International (2015)

Nearly half the population of Sierra Leone is under the age of 18 years and the impact of the Ebola crisis on their lives now and on their future opportunities has been far-reaching: no school; loss of family members and friends to the virus; and changing roles and responsibilities in the home and t... more

External Link

Acute Chagas Disease: New Global Challenges for an Old Neglected Disease

Andrade, D.; Gollob, K.; Dutra, W. PLoS Neglected Tropical diseases (2015) CC

Abstract: Chagas disease is caused by infection with the protozoan Trypanosoma cruzi, and although over 100 years have passed since the discovery of Chagas disease, it still presents an increasing problem for global public health. A plethora of information concerning the chronic phase of human Chaga... more

Download (471)

View PDF (697)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (334)

View PDF (306)

Quick guide to video-supported treatment of tuberculosis (2020)

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

Despite being a curable and preventable disease, tuberculosis (TB) remains as one of the major challenges for health systems, globally. Every year, TB affects more than 10 million people and kills more than 1.4 million people. WHO’s Digital Health for the End TB Strategy – an Agenda for Action o... more

Download (313)

View PDF (340)

Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination

World Health Organization WHO (2022) C_WHO

Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine method... more

Download (325)

View PDF (402)

Leprosy Programme and Transmission Assessment

World Health Organisation (WHO) (2023) C_WHO

The Leprosy Programme and Transmission Assessment (LPTA) is an activity that is carried out by internal teams towards the end of Phase 1 (see Leprosy Elimination Framework in the Annex) when a subnational jurisdiction (typically second-tier) reaches the milestone for interruption of transmission, i.... more

Download (306)

View PDF (438)

Operational guidance on the use of yellow fever assays in the context of surveillance

World Health Organization WHO (2023) C_WHO

This publication aims to provide updated guidance on the specific use of yellow fever laboratory assays in the context of surveillance to be used across the Global Yellow Fever Laboratory Network for disease surveillance. In the recent years, new commercial assays became available and are now recomm... more

Download (457)

View PDF (462)

Out of the Shadows. Making Mental Health a Global Development Policy
recommended

Seth Mnookin World Bank Group, and World Health Organization WHO (2016) C_WHO

Mental disorders impose an enormous burden on society, accounting for almost one in three years lived with disability globally. •In addition to their health impact, mental disorders cause a significant economic burden due to lost economic output and the link between mental disorders and costly, po... more

Download (282)

View PDF (517)

U.S. Government Global Nutrition Coordination Plan 2021-2026 - World

US Agency for International Development (2021) C2

English Manual and Guideline on World about Food and Nutrition, Health and Epidemic; published on 30 Nov 2021 by USAID

External Link

WHO guideline on control and elimination of human schistosomiasis
recommended

World Health Organization WHO (2022) CC

Schistosomiasis is a public health problem in tropical and subtropical regions of Africa, Asia, the Caribbean and South America. It is one of the neglected tropical diseases (NTDs) - a group of diseases and conditions that affect particularly low-income populations, worldwide. Last year, WHO laun... more

External Link

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Senegal

Africa Center for Disease Control and Prevention (2023) CC

The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr... more

Download (505)

View PDF (676)

World Urbanization Prospects: The 2018 Revision. Key facts

United Nations Populations Division (2018) CC

Globally, more people live in urban areas than in rural areas, with 55 % of the world’s population residing in urban areas in 2018. In 1950, 30 % of the world’s population was urban, and by 2050, 68 % of the world’s population is projected to be urban.

Download (462)

View PDF (375)

Air quality index Nepal Fact Sheet 2022

Greenstone, M.; C. Hasenkopf and K. Lee University of Chicago’s Energy Policy Institute (2022) C1

Nepal is the world’s third most polluted country. Air pollution shortens average Nepalese life expectancy by 4.1 years, relative to what it would be if the World Health Organization (WHO) guideline of 5 μg/m3 was met.1 The highest concentrations of air pollution are observed in Nepal’s southwes... more

Download (504)

View PDF (439)

WHO Emergency Response Framework - Internal WHO procedures - Second Edition

World Health Organization WHO (2024) C_WHO

The ERF provides WHO staff with essential guidance on how the Organization manages the assessment, grading and response to public health events and emergencies with health consequences, in support of Member States and affected communities. The ERF adopts an all-hazards approach and it is therefore a... more

Download (935)

View PDF (599)

Rehabilitation of people with physical disabilities in developing countries

Sexton, S. USAID ; ISPO (2016) C1

Program Report for Collaborative Agreement: DFD-A-00-08-00309-00 September 30, 2008 -December 31, 2015

Download (284)

View PDF (319)

Ending Extreme Poverty: The Call from Catholic Social Thought

Miller A. Integritas (2015) C1

Integritas 4.3 (Fall 2014), pp. 1-30. doi: 10.6017/integritas.v4i3p1

Download (314)

View PDF (321)

In Danger: UNAIDS Global AIDS Update 2022
recommended

UNAIDS (2022) C_WHO

Progress in prevention and treatment is faltering around the world, putting millions of people in grave danger. Eastern Europe and central Asia, Latin America, and the Middle East and North Africa have all seen increases in annual HIV infections over several years. In Asia and the Pacific, UNAIDS da... more

Download (166)

View PDF (133)

Prevalence of clinical forms of Chagas disease: a systematic review and meta-analysis – data from the RAISE study

Nasciemento, B.R.; et al. (2024) CC

The Lancet Regional Health - Americas 2024;30: 100681 Published Online 3 February 2024 https://doi.org/10.1016/j.lana.2024.100681

Download (460)

View PDF (567)

Guidelines for Strengthening of Tertiary Care of Cancer

Ministry of Health & Family Welfare, India (2013) CC

under National Program for Prevention and Control of Cancer, Diabetes, CVD & Stroke (NPCDCS) in 12th five year plan (2012-17)

Out of the Shadows. Making Mental Health a Global Development Policy recommended

WHO guideline on control and elimination of human schistosomiasis recommended

In Danger: UNAIDS Global AIDS Update 2022 recommended

Out of the Shadows. Making Mental Health a Global Development Policy
recommended

WHO guideline on control and elimination of human schistosomiasis
recommended

In Danger: UNAIDS Global AIDS Update 2022
recommended